Viking Therapeutics
VKTX
184 hedge funds and large institutions have $1.11B invested in Viking Therapeutics in 2023 Q1 according to their latest regulatory filings, with 75 funds opening new positions, 48 increasing their positions, 46 reducing their positions, and 19 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
295% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 19
255% more capital invested
Capital invested by funds: $312M → $1.11B (+$795M)
228% more call options, than puts
Call options by funds: $83.9M | Put options by funds: $25.5M
43% more funds holding
Funds holding: 129 → 184 (+55)
40.25% more ownership
Funds ownership: 44.5% → 84.75% (+40%)
4% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$113M |
| 2 |
State Street
Boston,
Massachusetts
|
+$52M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$20.2M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$17.6M |
| 5 |
DM
Deerfield Management
New York
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$5.88M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$5.73M |
| 3 |
Millennium Management
New York
|
-$5.62M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$5.12M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$3.88M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Rockefeller Capital Management
New York
| – | -$13K | -1,461 | Closed |
|
|
SWA
202
SOA Wealth Advisors
New York
| – | -$11.6K | -1,230 | Closed |
|
VKTX Hedge Fund Activity: Q1 2023 in Review
184 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q1 2023, worth a combined $1.11B — up 255% from $312M a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new VKTX positions and 19 closed out — a net gain of 56 holders — while 48 added to existing stakes and 46 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $113M. The largest seller was Two Sigma Investments, cutting an estimated $5.88M.
- 184 institutional investors held Viking Therapeutics (VKTX) as of Q1 2023, up from 129 in Q4 2022.
- Funds reported $1.11B of Viking Therapeutics stock for Q1 2023, up 255% quarter-over-quarter.
- 75 funds opened new Viking Therapeutics positions in Q1 2023 and 19 closed out, a net change of +56 holders.
- The largest Viking Therapeutics buyer in Q1 2023 was Fidelity Investments, an estimated $113M added.
- The largest Viking Therapeutics seller in Q1 2023 was Two Sigma Investments, an estimated $5.88M sold.
Based on aggregated 13F filings for Q1 2023.